News Releases:


miRagen Therapeutics Adds Biotech and Pharmaceutical Industry Veterans to Senior Leadership Team

Christopher J. Morl, M.B.A., B.Sc. (Hons), Joins as Chief Business Officer Aimee L. Jackson, Ph.D., Joins as Director of Target Development   BOULDER, Colo., June 11, 2013 –  miRagen Therapeutics, Inc., a biopharmaceutical company discovering and developing innovative microRNA... View »

miRagen Therapeutics Achieves First Milestone in Strategic Alliance with Servier

Servier selects third cardiovascular target triggering the first milestone under the collaboration SURESNES, France, and BOULDER, Colo., May 23, 2013 – Servier, a privately-run French research-based pharmaceutical company and a major player in Europe and emerging markets having expertise... View »

miRagen Therapeutics, Inc. Exclusively Licenses Intellectual Property from the University of Glasgow for microRNA-145 Targeting in the Treatment of Pulmonary Arterial Hypertension

IP generated as a result of collaboration between researchers from miRagen, the University of Glasgow and the University of Cambridge Preliminary results in pre-clinical models show significant promise in treatment of a disease with very high unmet medical need... View »

Santaris Pharma A/S and miRagen Therapeutics Inc. expand worldwide strategic alliance to discover and develop LNA-drugs against disease-causing microRNAs

Hørsholm, Denmark / Boulder, Colorado USA, January 8, 2013. — Santaris Pharma A/S and miRagen Therapeutics, Inc. today announced that they have expanded their existing partnership in the field of microRNA therapeutics. Under the expanded agreement, miRagen obtains a... View »